Screener
AngioDynamics ANGO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Non-cash lease expense | 1,555 | 1,958 | 1,931 |
| Non-cash interest expense | 290 | — | — |
| Goodwill impairment | — | — | 159,476 |
| Stock based compensation | 13,960 | 9,772 | 10,529 |
| Gain on dispositions | — | — | (54,499) |
| Transaction costs for disposition | — | — | (5,084) |
| Change in fair value of contingent consideration | — | 272 | 432 |
| Deferred income tax provision | 143 | (988) | (7,968) |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's stock-based comp?
- AngioDynamics (ANGO) reported stock-based comp of $3.92M in Q1 2026.
- How has AngioDynamics's stock-based comp changed year-over-year?
- AngioDynamics's stock-based comp increased by 138.6% year-over-year, from $1.64M to $3.92M.
- What is the long-term trend for AngioDynamics's stock-based comp?
- Over 4 years (2022 to 2026), AngioDynamics's stock-based comp has grown at a 6.9% compound annual growth rate (CAGR), from $10.69M to $13.96M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about AngioDynamics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude